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Abstract
Introduction: The field of diagnostics for active tuberculosis (TB) is rapidly developing. TB diagnostic modeling can help to
inform policy makers and support complicated decisions on diagnostic strategy, with important budgetary implications.
Demand for TB diagnostic modeling is likely to increase, and an evaluation of current practice is important. We aimed to
systematically review all studies employing mathematical modeling to evaluate cost-effectiveness or epidemiological
impact of novel diagnostic strategies for active TB.
Methods: Pubmed, personal libraries and reference lists were searched to identify eligible papers. We extracted data on a
wide variety of model structure, parameter choices, sensitivity analyses and study conclusions, which were discussed during
a meeting of content experts.
Results & Discussion: From 5619 records a total of 36 papers were included in the analysis. Sixteen papers included
population impact/transmission modeling, 5 were health systems models, and 24 included estimates of cost-effectiveness.
Transmission and health systems models included specific structure to explore the importance of the diagnostic pathway
(n = 4), key determinants of diagnostic delay (n = 5), operational context (n = 5), and the pre-diagnostic infectious period
(n = 1). The majority of models implemented sensitivity analysis, although only 18 studies described multi-way sensitivity
analysis of more than 2 parameters simultaneously. Among the models used to make cost-effectiveness estimates, most
frequent diagnostic assays studied included Xpert MTB/RIF (n = 7), and alternative nucleic acid amplification tests (NAATs)
(n = 4). Most (n = 16) of the cost-effectiveness models compared new assays to an existing baseline and generated an
incremental cost-effectiveness ratio (ICER).
Conclusion: Although models have addressed a small number of important issues, many decisions regarding
implementation of TB diagnostics are being made without the full benefits of insight from mathematical models. Further
models are needed that address a wider array of diagnostic and epidemiological settings, that explore the inherent
uncertainty of models and that include additional epidemiological data on transmission implications of false-negative
diagnosis and the pre-diagnostic period.
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Introduction
The last decade has seen a dramatic increase in the
development of novel diagnostic tests for active tuberculosis (TB)
[1–4]. As a result policy makers must decide what novel
diagnostics to implement with the limited resources available to
them. To date the contribution of modeling to decision-making
processes has been limited; despite the rapid growth of interest in
TB diagnostics, in many cases models are not available to aid
decision-making, particularly within country. As policy makers
face questions about implementation of novel diagnostic strategies
with substantial budgetary implications, the demand for these
models will increase. Given the wide variety in modeling
approaches, methods and objectives, both those developing and
those using models can benefit from a synthesis and evaluation of
current TB diagnostic modeling practices.
The development of novel diagnostics is not limited to
technological advancements, but includes novel diagnostic algo-
rithms and systems of diagnosis that allow novel or existing
diagnostic tools to affect changes in clinical practice leading to
improved patient outcomes[1–4]. Novel tests may boast a range of
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improved attributes. However the impact of any novel test
depends on how that test is implemented and for what intended
population. Novel tools cannot benefit TB patients unless they lead
to earlier or more appropriate initiation of treatment. Likewise,
evaluations of novel tests should account for the role of empiric
therapy as individuals may still be treated in the absence of a
positive test result, and this can have important implications on the
impact of novel tools. New technologies are often (although not
always) accompanied by increased costs, relating to the test itself
and/or the systems into which they are implemented. In the face
of multiple technological options and even more potential
algorithms and implementation plans, deciding which novel
diagnostic(s) to implement, and how, is a very complex process
[5]. Such decisions must involve careful consideration of available
strategies, requiring an understanding of the potential costs,
population level impact for each test upon implementation in a
given setting and uncertainty around these factors. Mathematical
modeling, including transmission modeling, health systems mod-
eling and economic evaluation can help to make these decision-
making processes more transparent and data-driven; in the
absence of such models, it is difficult to utilize existing data in a
systematic fashion for decision-making.
The objectives of this paper were to systematically review all
studies employing mathematical modeling to explore the potential
epidemiological impact and/or cost-effectiveness of novel diag-
nostic tests for TB and to identify and discuss key methodological
challenges and limitations of existing models and gaps in empirical
evidence required to populate such models. This review was
undertaken within the context of the TB Modelling and Analysis
Consortium (TB MAC) meeting on modeling of novel TB
diagnostics, where preliminary results were discussed.
Methods
We carried out a systematic literature review to identify existing
TB modeling papers that evaluated novel tools or algorithms to
diagnose active TB. Our focus was to identify models exploring
novel diagnostic technology or models concerned with under-
standing the TB diagnostic pathway. Models that explored the
impact of alternative case finding approaches not related to new
diagnostic tools (e.g. active versus passive case finding) were not
included.
Search strategy
The medical literature was searched for relevant studies in
PUBMED; the detailed search string is included in the supple-
mentary material. Personal libraries of TB MAC members were
searched for modeling papers (free text search for ‘model’), and
mathematical modeling journals were scanned for any papers
describing TB models. Within this set of retrieved citations,
potentially relevant records were identified through a text search
for ‘diagn’ OR ‘test’ OR ‘screen’. Citations of all selected original
articles [6] published after the 1st of January 2000 to March 1st
2013, were reviewed. The database of relevant citations is
regularly updated by TB MAC and available online at: http://
www.tb-mac.org/Resources/.
Inclusion and exclusion criteria
Papers were eligible for inclusion if they were written in English
and published after the 1st of January 2000 to restrict to recent
diagnostic strategies with relevance to current policy decisions.
Papers were excluded if the model focused on diagnosing latent
TB infection, or evaluated only diagnostic tools that fell within the
existing standard of care at the time of publication, based on our
understanding of TB diagnostic practices. Therefore this review
was focused on modelling novel diagnostic tools or algorithms for
active TB that are NOT currently in use as the standard of care.
For the purposes of this review, the Xpert MTB/RIF test (Xpert,
Cepheid Inc., CA, USA) was not yet considered as standard of
care in any setting. The selected papers were independently
assessed by two reviewers (AZ and RMGJH) for inclusion and all
included studies underwent double data extraction by the same
two reviewers; disagreements were resolved through consensus. In
defining ‘mathematical model’ we followed Garnett et al [7] and
included decision analytic, transmission, operational or within-host
models, but excluded purely statistical models and studies using
models to only estimate resource requirements without corre-
sponding measures of health-related outcomes [8].
Papers were grouped into three subject areas that were not
mutually exclusive: 1) population level impact/transmission,
defined as models including a transmission component or
measuring epidemiological impact at the population level; 2)
health systems, defined as models including compartments that
represent points of interactions between patient and health care
providers or institutions; and 3) model based cost-effectiveness and
cost-utility analyses, following the definitions by Drummond et al.
[8]. To further clarify these definitions, transmission modeling
generally assesses the population level impact of interventions in
terms of changes in TB incidence, TB prevalence or TB mortality
over time and can estimate the potential future benefit of
introducing a novel diagnostic intervention on those population-
level outcomes. Health systems models, which may include
transmission and economic evaluations, involve explicitly model-
ing the interaction between patients and the health system or
health care provider. These models are important for evaluating
TB diagnostic interventions in the local context and can improve
our understanding of operational elements such as patient and
diagnostic delay or other key elements of the patient–provider
interaction that may influence a test’s potential impact and costs.
We followed the definitions of Drummond et al. for cost-
effectiveness and cost-utility analyses, including any type of model
(transmission, health system, cohort, etc.) that includes a compar-
ison of two or more alternative strategies both in terms of costs and
consequences (efficacy or effectiveness) [8]. Economic evaluations
can rely on many different types of models, but economic
evaluations are defined by the study purpose or question they are
answering (cost-effectiveness, budget impact, etc.), using different
types of models to answer different economic questions. Decision
analysis and Markov models are the most common approach for
evaluating cost-effectiveness of novel diagnostics; however cost
components can also be added to transmission or health systems
models.
Data extraction and synthesis
For all papers information was extracted pertaining to the
research question and result. Extracted data included: details of
the population and diagnostics pathways that were explored,
model methodology (model type, sensitivity analyses, details of
model structure) and, where appropriate, details on how the cost-
effectiveness analysis was conducted, including questions about the
costing perspective employed and scope of the costing parameters.
A complete summary of all data extracted is available in the
supplementary material. The results were discussed by a broad
group of experts during the TB MAC meeting on ‘‘Impact and
cost-effectiveness of current and future diagnostics for TB’’ in
Amsterdam, April 24–25th 2013 (www.tb-mac.org/WorkAreas/
WorkArea/4).
TB Diagnostics Modeling: A Systematic Review
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Results and Discussion
Out of 5619 unique records that were found in the literature
search, 91 records were selected for evaluation, of which 46
underwent full-text evaluation. After full-text screening 31 papers
were selected. Consultation with experts in the field yielded five
additional papers; therefore 36 papers were included for data
extraction (see Figure 1). The complete summary of all included
papers and extracted data is available in Table S1.1 thru Table
S3.4 in Data S1.
Is enough modeling being done?
Since the approval of Xpert in 2010, a sharp increase in TB
diagnostic modeling has been seen both among papers modeling
Xpert and among papers evaluating alternative nucleic acid
amplification tests (NAATs). Compared with only 8 TB modeling
papers published from 2000–2007 inclusive (approximately one
per year), 10 TB diagnostic modeling papers were published in
2012, 6 of which focused on Xpert.
The 36 included papers were grouped into the three non-
exclusive categories: 16 papers included population impact/
transmission modeling, 5 were health systems models, and 24
included cost-effectiveness models. Novel tests evaluated across the
35 papers included: several NAATs, light-emitting diode (LED)
microscopy, Determine TB-LAM (Alere Inc., MA, USA) a lateral-
flow urine lipoarabinomannan detection assay, FastPlaque TB and
FastPlaque-Response (Biotec Labs Ltd, UK), serological tests
including Anda TB (Anda Biologicals, Strasbourg), MTT assay, a
non-commercial colorimetric assay (ICN Biomedicals) and sputum
processing methods including bleach sedimentation and sample
Figure 1. Systematic review flowchart for selection of papers.
doi:10.1371/journal.pone.0110558.g001
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dilution. A table of novel TB diagnostic tests included in the
evaluated studies with brief descriptions is included in Table 1.
Novel diagnostic strategies included the expansion of culture, drug
sensitivity testing (DST), chest x-ray and mass miniature radiog-
raphy (MMR). Several hypothetical diagnostic tests, scenarios or
algorithms were also evaluated including: hypothetical NAATs
with improved speed, sensitivity and specificity; a dipstick style test;
rapid DST; tests resulting in reduction in diagnostic delay; and
rapid point of care with improved sensitivity, specificity and
reduced time to results compared to smear microscopy or
conventional drug susceptibility testing (Tables S1.2, S2.2 &
S3.3 in Data S1).
The majority of studies (83%, 30/36) modelled high TB
incidence settings; 39% (14/36) of evaluated studies modelled the
South African setting specifically, reflecting the large burden of TB
in South Africa and the recent move and investments towards
novel technologies in improving TB control. Only 6/36 (17%)
studies -all cost-effectiveness analyses- modelled low TB incidence
settings including the United States, United Kingdom, and
Finland. While the majority of studies are modelling settings with
the highest TB burden, many important epidemiological settings
(e.g., China, Southeast Asia outside of India) have few or no
models to provide insight into potential cost-effectiveness or
epidemiological impact of novel diagnostics or diagnostic strate-
gies. As a result decisions with important repercussions for the TB
epidemic and TB control budgets are frequently being made in the
absence of supporting insight that models could provide. As tests
and diagnostic algorithms are developed and evaluated, models
Table 1. Novel diagnostic tests for active TB disease evaluated in included modeling review.
Novel diagnostic tests evaluated Type of Diagnostic Method Sample type
Nucleic Acid Amplification
Tests (NAATs)
GeneXpert MTB/RIF (Xpert) (Cepheid,
USA)
NAAT Real-time PCR based technique to detect both presence
of MTB and RIF resistance using an automated cartridge
based design
Resp. spec.
INNO-LiPA Rif. TB (Immunogenetics,
Belgium)
Line probe A reverse hybridization-based line probe assay that
detects mutations is the rpoB ‘‘hotspot’’ gene region
(RIF resistance)
Resp. spec. and/or liquid/
solid culture
MTBDRplus (Hain Lifescience, Germany) Line-probe Molecular genetic assay for identification of resistance to
rifampicin and/or isoniazid. Mycobacterial DNA is
extracted from the specimen, specifically amplified via
PCR and detected on a membrane strip using reverse
hybridization and an enzymatic color reaction.
Resp. spec. and/or liquid/
solid culture samples
GenProbe Amplified Mycobacterium
Tuberculosis Direct Tests (MTD)
(Gen-Probe Inc., USA)
NAAT Transcription mediated amplification of rRNA, detects
Mycobacterium tuberculosis rRNA directly and rapidly
Resp. spec.
Cobas Amplicor (Roche Diagnostics) NAAT PCR amplification of 16s rRNA Resp. spec.
Non-NAAT based tests
LED Microscopy Microscopy Light Emitting Diode (LED) based fluorescence
microscope, energy-efficient, does not require
a dark room
Resp. spec.
FastPlaque-Response (Biotech, UK) Phage-based assay Allows for detection of Rifampicin resistance;
Phage-based assay that detects live MTB in a plaque
assay in a lawn of rapidly growing detector cells.
Samples are incubated with and without RIF overnight
Resp. spec.
FastPlaque TB (Biotech, UK) Phage-based assay Mycobacteriophage (virus that infect TB) - Phage-based
assay that detects live MTB in a plaque assay in a lawn
of rapidly growing detector cells.
Resp. spec.
MTT assay (ICN Biomedicals) Colorimetic assay Noncommercial colorimetric assay that uses an indicator
of cellular growth and viability whose oxidized yellow
form becomes purple after reduction to formazan by
the dehydrogenases of live bacterial cells
Liquid/solid culture samples
Bleach sedimentation on sputum
samples
Sputum processing to
increase dx yield
Bleach digestion of sputum, followed by specimen
concentration step such as sedimentation
Resp. spec.
Anda TB (Anda Biologicals,
Strasbourg)
Serological ELISA test ELISA based detection of antibodies elicited by antigens
of MTB that are recognized by humoral immune system
Blood samples
Diluting sputum before MTD
Gen-probe
Specimen processing 1:10 dilution of the processed specimen Resp. spec.
Determine TB-LAM (Alere, USA) Lateral-flow immune-
chromatographic assay
Lateral-flow immune-chromatographic assay detects
lipoarabinomannan (LAM) – an immunogenic glycolipid
in the cell way of MTB- in urine. First true POC test,
excellent specificity and higher sensitivity than sputum
smear microscopy in immuno-compromised adults
Urine samples
Abbreviations: MTB: Mycobacterium tuberculosis, RIF: rifampicin, PCR: polymerase chain reaction, POC: point-of care, ELISA: enzyme linked immune-sorbent assay, Resp.
Spec.: respiratory specimens, dx: diagnostic.
doi:10.1371/journal.pone.0110558.t001
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are needed that represent a wide range of diagnostic tests,
strategies and settings to help support data-driven policy decisions.
What questions are modelling studies trying to answer?
Models covered a wide range of objectives in evaluating novel
diagnostics. Transmission and health system models investigated
the impact of diagnostic delay (n = 5), and demonstrated several
key insights including a threshold for average delay to diagnosis
beyond which an epidemic will escalate [9], the importance of
applying novel diagnostics in both private and public health
systems to reduce diagnostic delay [10], and that test sensitivity
was a key determinant of diagnostic delay [11]. In prison
populations it was shown screening at entry and annually with
MMR could keep TB prevalence below 1% [12]. In the case of
drug-resistant TB, it was demonstrated that current strategies with
long delays to diagnosis will probably not halt the spread of MDR-
TB, and reducing the delay through improved access to DST and
second-line treatment may reduce transmission of drug-resistant
TB [13,14]. Transmission models highlighted the importance of
considering different elements of the diagnostic pathway (n= 4)
including the pre-diagnostic infectious period; others linked
operational and transmission models, demonstrating that opera-
tional context elements such as patient diagnostic delay, access to
care and loss to follow-up can inform setting specific models useful
for data-driven policy decisions [15–18].
In terms of economic evaluations, models provided comparisons
of the cost-effectiveness and impact on TB incidence and mortality
of various novel or hypothetical diagnostics and strategies (n = 24)
[16,19–41]. Many studies demonstrated the cost-effectiveness of
novel diagnostics, often highlighting the settings and implemen-
tation strategies and/or algorithms in which those tests were most
cost-effective. Among cost-effectiveness models, the most frequent-
ly studied diagnostic assays included Xpert MTB/RIF (n= 7) and
alternative NAATs (n= 4). Most (n = 16) of the cost-effectiveness
models compared new assays to an existing baseline and generated
an incremental cost-effectiveness ratio (ICER), of which 69%
(n= 11) concluded that novel TB diagnostics were likely to be cost-
effective relative to that baseline. Some technologies including
NAATs implemented in low TB prevalence settings were judged
not to be cost-effective [27,30], and serology was shown to be
more costly and less effective than existing diagnostics such as
sputum smear microscopy [28]. Cost-effectiveness studies also
highlighted barriers or challenges associated with roll-out of novel
diagnostic tests including operational barriers or increased indirect
costs, associated with HIV or multi-drug resistance (MDR) care
[19,25]. A transmission study demonstrated that DST for all
retreatment cases could be highly cost-effective [40]. Evaluations
of hypothetical point of care (POC) tests suggested that a highly
specific, low cost POC test would be highly cost-effective, with the
greatest impact in settings with poor infrastructure [37].
Do models include the relevant features?
In each of the three model categories we evaluated relevant
features associated with modelling methods, structure and
parameters including: outcomes of interest, type of model,
sensitivity and uncertainty analyses, costing methods and data
sources, how drug susceptibility and HIV status were incorporated
in the model along with false negatives and positives.
Population impact/transmission models. Sixteen (44%)
of the selected papers employed a transmission model to assess the
population impact of a novel TB diagnostic [9–20,40,42–44]
(Table S1.1 in Data S1). The main outcomes of interest included:
TB incidence, TB mortality, incidence of multi-drug resistant TB
(MDR-TB) or extensively drug resistant TB (XDR-TB), and
transmission rate. All papers focused on implementation in a
population with a high TB burden and/or low or middle income
setting, with the exception of one theoretical analysis that assessed
high, medium and low TB burden settings [15]. Seven of 16
studies (44%) explored methods of TB diagnostic modeling; for
example: linking transmission modeling and discrete event
simulation (n= 2) [16,18], including patient–provider interactions
(n = 1) [10], assessing implications of periods of pre-diagnostic
transmission (n= 1) [15] or modeling details of the diagnostic
pathway or diagnostic delay (n = 3) [9,11,17]. A dynamic
compartmental model was employed in 7/16 (44%) of the
transmission studies evaluated [9,12,15,17,42–44]; the remaining
studies linked a compartmental model with an operational model
(n = 3) [13,16,18], a Markov model (n = 1) [10], a state transition
model [40], a cost-effectiveness analysis (n = 1) [19], two decision
analysis models [11,40], a cohort model (n = 1) [9] or a Markov
model with a cost-effectiveness component (n = 1) [20]. Drug
susceptibility and HIV status were each considered in 8/16 (50%)
studies and 7/16 studies respectively, 4/16 (25%) considered both
in the same model [13,16,19,43].
Health systemmodels. Only 5/36 (14%) of included papers
explicitly modelled interactions between patients and health care
providers or health care facilities [10,13,16–18]. All models
assessed populations in settings with a high TB burden and all
were published in the last five years (Table S2.2 in Data S1).
Outcomes of interest included TB incidence and prevalence, TB
mortality and rates of transmission. One study also assessed costs
and number of patients cured [16]. This was the only study from
this group to evaluate novel diagnostics (i.e.: LED and Xpert) as
opposed to a hypothetical test or a decrease in the delay to
diagnosis [16]. All 5 studies employed a transmission model; two
employed discrete event simulation [16,18], one [10] employed a
Markov structure and one [13] a queuing structure. Four of 5
studies (80%) [10,13,16,18] explicitly modelled the period of
transmission pre-diagnosis (Table S2.3 in Data S1). Two studies
[13,16] included both HIV status and drug susceptibility in the
model while a further study considered only HIV status [17].
Two of 5 studies (40%) were calibrated to empirical data
[10,17]: one employing epidemiological characteristics of the TB
and HIV epidemic in the modelled country [19] and the other
employing study data evaluating patient-provider interactions
[17]. One study (20%) considered false positives [16], while 3/5
(60%) explicitly modelled false negatives allowing re-entry into the
same diagnostic pathway [10,16,17].
Future transmission and health systems models would benefit
from careful consideration of the transmission patterns in the pre-
diagnostic phase of disease development as well as among
individuals receiving false-negative diagnoses. Several factors
might contribute to differential transmission during these periods,
including the duration of continued infectiousness in each time
period, the trajectory of infectiousness over time and changes in
contact structure over time. For example, if the majority of the
transmission occurs prior to the patient seeking care, improved
sensitivity and specificity of a novel diagnostic may not impact
upon transmission and therefore TB incidence. Molecular
epidemiology studies and emerging technologies including whole
genome sequencing coupled with intensive contact tracing studies,
may serve to provide improved understanding of these factors in
the future, and to ultimately to help better model the impact of
novel diagnostics on transmission. Modellers should also carefully
consider the trajectory of false negative patients through the
diagnostic pathway across different operational contexts. Do false
negative diagnoses result (on average) in many months of high-
level transmission, just a few weeks of contact only with people
TB Diagnostics Modeling: A Systematic Review
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who are already exposed, or death with very little on-going
transmission? Studies involving intensive follow-up of representa-
tive groups of people testing negative for TB in given settings could
provide helpful data in understanding how many false negatives
ultimately become diagnosed with TB, when diagnosis occurs and
what happens to those who are not diagnosed with TB. Data
collection in these areas should be encouraged to better inform
models seeking to appropriately address these challenging
considerations.
Cost-effectiveness models. Twenty-four out of the 36
selected papers (67%) included a cost-effectiveness or cost-utility
analysis [16,19–41]. Twenty out of 24 studies (83%) were cohort
models, including either a decision analysis framework [21–23,25–
38,41], or Markov approach [20,24,26]; 3/24 (12.5%) were
transmission models [16,19,40], one study linked a cohort
(Markov) and transmission model [20], and one transmission
model also utilized a health systems approach [16]. The majority
of cost-effectiveness models, 16/24 (67%), took their study
population as people with TB symptoms or in the case of DST
individuals diagnosed with TB [21–23,25–37]; remaining studies
assessed HIV populations initiating ART [24,39,41], the general
population [16,19,40], or a prison population with high MDR
prevalence [20,38] (Table S3.1 in Data S1). Most models assessed
populations in high TB burden settings, however 5/24 (21%) were
set in low TB burden countries [27,29,30,33,38]. Eight of 24
(33%) studies evaluated Xpert [16,19–21,24,32,34,36], while 9/24
(37.5%) evaluated an alternative NAAT [22,27,29–34,36]. Effec-
tiveness measures in these analyses included health utility measures
[quality-adjusted life years (QALYs), 4/24 (17%), or disability-
adjusted life years (DALYs), 7/24 (29%)] and cases detected; 16/
24 studies (67%) generated an ICER (Table S3.2 in Data S1).
Several studies also calculated total program and/or implemen-
tation costs. The cost-effectiveness studies were performed from
either a health care provider, health system, TB program or TB
laboratory perspective. Only one study included patient costs [25],
and these were restricted to an approximate estimate of cost of
travel to the health facilities. No study reported taking a societal
perspective. Less than half (11/24, 46%) employed an empirical
costing component in the analysis [16,20,22,25–
27,29,33,36,40,41]. Fifteen of 24 studies (62.5%) included HIV
in the model [16,19–21,23,24,26,28,32,34–39,41], and 11/24
(46%) accounted for drug susceptibility status [16,19,22,24,30,32–
34,36,38,40].
There exists a scarcity of models that include the costs incurred
by TB patients throughout the diagnostic and treatment process,
and no cost-effectiveness studies were conducted from the patient
or society perspective. Omission of the patient or societal
perspective may underestimate the costs and/or impact associated
with earlier or more effective diagnosis. Estimation of patient costs
may be important for other models as well; for example, if patient
costs of transport and TB diagnosis are catastrophically high, the
incremental impact of point-of-care diagnostics (i.e., that do not
require multiple visits to healthcare facilities to initiate treatment)
may be much greater than if patient costs are low. As TB is a
disease of poverty, closer evaluation of the patient-level costs of TB
diagnosis may reveal that these costs are a critical barrier to the
impact of novel diagnostic tests [45]. Increased effort should be
made to collect empirical cost data from the patient and societal
perspective in a variety of settings; and/or incorporate existing
data into current models.
Moreover, many cost-effectiveness analyses claiming a health
systems, health care provider or TB program perspective did not
include all relevant costs. Some studies included only test costs and
salaries, omitting overhead costs; likewise costs associated with
HIV care post-TB diagnosis and MDR-TB treatment post-
diagnosis with Xpert or other new diagnostics, were not
systematically included across relevant studies. Reviewed studies
demonstrated that the inclusion or omission of indirect costs,
particularly costs associated with HIV and MDR care, can have
important implications for estimated ICERs and model conclu-
sions, and should be carefully considered in cost-effectiveness
studies. While often challenging to distinguish the extent to which
direct provider costs and higher-level program costs are incre-
mental, omission of these costs may lead to overly optimistic
conclusions surrounding the cost-effectiveness of novel interven-
tions. Cost-effectiveness analyses should carefully consider relevant
costs and endeavour to include clear explanations of which costs
are and are not included and why.
Is uncertainty properly captured?
Sensitivity analyses were performed in 14/16 transmission
studies (87.5%), yet only 6 considered variation in two or more
variables at a time [12,15,17,19,40,43] (Table S1.3 in Data S1).
Half of the papers calibrated their models to existing real data (e.g.
incidence trends or point estimates). Among the 16 transmission
studies evaluated, 13 (81%) explicitly accounted for the impact of
transmission before diagnosis. The impact of individuals with false
negative diagnoses (i.e. patients with active TB who were
misdiagnosed as TB negative and therefore continued to transmit)
was estimated in 6/16 studies (37.5%) [10,11,16,17,19,43], of
which 5 assumed that these patients would re-enter into the same
diagnostic pathway at the same rate as ‘pre-diagnostic’ individuals
with active TB. Three health systems studies (60%) performed
sensitivity analyses [13,16,17], only one of which considered more
than one variable at a time [17].
All economic studies performed sensitivity analyses, and 13/24
(54%) assessed sensitivity to more than one variable at a time
[19,20,22,23,26–28,33–37,39,40] (Table S3.4 in Data S1). Four-
teen of 24 (58%) explicitly modelled false positives
[16,19,22,24,26–28,30,31,33,35,39,41] (which may have an im-
pact on costs as patients then receive unnecessary treatment and
follow-up), 14/24 (58%) studies explicitly modelled false negatives
[16,19,20,22–24,26,28,30,31,34,36,39,41] (which may have an
impact on health outcomes as they remain undiagnosed, untreated
and potentially infectious), Only three studies allowed false
negatives to re-enter the diagnostic pathway, in two cases entering
the same diagnostic pathway as those entering for the first time
[16,26] and in the third a second pathway for false negatives was
modelled [39].
Sensitivity analyses were frequently limited to one- or two- way
analyses. More recent models increasingly include multi-way
sensitivity analyses as well; however, thorough investigation and
discussion of both uncertainty in model structures and parameter
values (both point estimates and associated ranges) remains a
largely unmet need. More transparent approaches to uncertainty
may help to build understanding and trust in modelling
approaches among policy makers.
Most models evaluated do not generate predictions that can be
validated against data collected in the future; therefore this
systematic review is limited in its ability to assess whether model
predictions could be validated in real life. This review is also
limited by its ability to review only English language publications.
Conclusion
As highlighted in this review, models have provided helpful
insight both in terms of pragmatic policy implications concerning
the cost-effectiveness of novel diagnostics and methodological
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insights. Models have highlighted the scenarios and algorithms
where novel technologies are most cost-effective, demonstrating
that while Xpert and other NAATs are highly cost-effective in
high TB burden settings, they are not cost-effective in settings with
low TB prevalence [19,20,27,30,36]. Similarly, serology in India
was shown to be both more costly and less effective than standard
smear microscopy contributing to important policy implications to
discourage use of serology at the national and global levels [28].
Models have provided insight on the potential impact of novel
diagnostics on transmission of TB over time; implementation of
Xpert in five African countries was shown to have the potential to
reduce TB incidence and mortality over ten years but increase
costs associated with MDR treatment and HIV care [19]. The
importance of explicitly modelling the pre-diagnostic infectious
period was demonstrated in transmission models that further
assessed how different characterizations of this infectious period
may have important implications on model results and interpre-
tations. Diagnostic delay was examined in several transmission
models, along with the identification of key determinants, such as
test sensitivity and the health system’s ability to return results to
the patient and initiate timely treatment. Finally, models have
highlighted the importance of the operational context stressing the
need for setting-specific operational or health systems models to
guide and support data-driven policy decisions.
The literature on novel TB diagnostic modeling remains limited
but is growing rapidly with the on-going development and
introduction of novel diagnostic assays and diagnostic systems.
We have identified and reviewed a group of models that may help
to inform decisions related to implementation of novel TB
diagnostics, but further models are needed that include additional
epidemiological settings and compare additional diagnostic
algorithms. These models would benefit tremendously from
epidemiological data on the transmission implications of false-
negative diagnosis and the pre-diagnostic period. Improvement
and expansion of mathematical models describing transmission,
health systems, and cost-effectiveness of novel TB diagnostics will
ensure more rational implementation and resource allocation of
these tools in order to realize their potential to improve human
health in high TB burden settings.
Supporting Information
Checklist S1 Prisma Checklist.
(DOC)
Data S1 Supplementary tables. Table S1.1, General
overview of population impact/transmission model. Table S1.2,
What was modeled (diagnostics and scope of model). Table S1.3,
Modeling methods. Table S2.1, Health System models: General
overview. Table S2.2, Cost-effectiveness specific considerations.
Table S2.3, What was modeled (diagnostics and scope of model).
Table S2.4, Modeling methods (including which mixed methods
were applied). Table S3.1, Cost-effectiveness models: General
overview. Table S3.2, Cost-effectiveness specific considerations.
Table S3.3, What was modeled (diagnostics and scope of model).
Table S3.4, Modeling methods.
(DOCX)
Acknowledgments
We thank Sourya Shrestha and Gwen Knight for valuable comments on an
early draft of this paper.
Author Contributions
Conceived and designed the experiments: AZ RGW AV TC DWD
RMGJH. Performed the experiments: AZ RMGJH. Analyzed the data: AZ
RMGJH. Wrote the paper: AZ RGW AV TC DWD RMGJH.
References
1. Boehme CC, Saacks S, O’Brien RJ (2013) The changing landscape of diagnostic
services for tuberculosis. Semin Respir Crit Care Med 34: 17–31.
2. McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, et al. (2012)
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances,
and opportunities. J Infect Dis 205 Suppl 2: S147–158.
3. Pai M, Minion J, Steingart K, Ramsay A (2010) New and improved tuberculosis
diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 16:
271–284.
4. Pai M, O’Brien R (2008) New diagnostics for latent and active tuberculosis: state
of the art and future prospects. Semin Respir Crit Care Med 29: 560–568.
5. Dowdy DW, Cattamanchi A, Steingart KR, Pai M (2011) Is scale-up worth it?
Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med 8:
e1001063.
6. Bacaer N, Ouifki R, Pretorius C, Wood R, Williams B (2008) Modeling the joint
epidemics of TB and HIV in a South African township. J Math Biol 57: 557–
593.
7. Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N (2011) Mathematical
models in the evaluation of health programmes. Lancet 378: 515–525.
8. Drummond M, Sculpher M, Torrance G, O’Bruen B, Stoddart G (2005)
Methods for the economic evaluation of health care programmes. Oxford:
Oxford University Press.
9. Uys PW, Warren RM, van Helden PD (2007) A threshold value for the time
delay to TB diagnosis. PLoS One 2: e757.
10. Dye C (2012) The potential impact of new diagnostic tests on tuberculosis
epidemics. Indian J Med Res 135: 737–744.
11. Millen SJ, Uys PW, Hargrove J, van Helden PD, Williams BG (2008) The effect
of diagnostic delays on the drop-out rate and the total delay to diagnosis of
tuberculosis. PLoS One 3: e1933.
12. Legrand J, Sanchez A, Le Pont F, Camacho L, Larouze B (2008) Modeling the
impact of tuberculosis control strategies in highly endemic overcrowded prisons.
PLoS One 3: e2100.
13. Basu S, Friedland GH, Medlock J, Andrews JR, Shah NS, et al. (2009) Averting
epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci U S A
106: 7672–7677.
14. Uys PW, Warren R, van Helden PD, Murray M, Victor TC (2009) Potential of
rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in
communities where Mycobacterium tuberculosis infections are highly prevalent.
J Clin Microbiol 47: 1484–1490.
15. Dowdy DW, Basu S, Andrews JR (2013) Is passive diagnosis enough?: the
impact of subclinical disease on diagnostic strategies for tuberculosis.
Am J Respir Crit Care Med 187: 543–551.
16. Langley I, Doulla B, Lin HH, Millington K, Squire B (2012) Modelling the
impacts of new diagnostic tools for tuberculosis in developing countries to
enhance policy decisions. Health Care Manag Sci 15: 239–253.
17. Lin HH, Dowdy D, Dye C, Murray M, Cohen T (2012) The impact of new
tuberculosis diagnostics on transmission: why context matters. Bull World
Health Organ 90: 739–747A.
18. Lin HH, Langley I, Mwenda R, Doulla B, Egwaga S, et al. (2011) A modelling
framework to support the selection and implementation of new tuberculosis
diagnostic tools. Int J Tuberc Lung Dis 15: 996–1004.
19. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA (2012) Population
health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/
RIF: a dynamic simulation and economic evaluation. PLoS Med 9: e1001347.
20. Winetsky DE, Negoescu DM, DeMarchis EH, Almukhamedova O, Door-
onbekova A, et al. (2012) Screening and rapid molecular diagnosis of
tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness
analysis. PLoS Med 9: e1001348.
21. Abimbola TO, Marston BJ, Date AA, Blandford JM, Sangrujee N, et al. (2012)
Cost-Effectiveness of Tuberculosis Diagnostic Strategies to Reduce Early
Mortality Among Persons With Advanced HIV Infection Initiating Antiretro-
viral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 60:
e1–e7 10.1097/QAI.1090b1013e318246538f.
22. Acuna-Villaorduna C, Vassall A, Henostroza G, Seas C, Guerra H, et al. (2008)
Cost-effectiveness analysis of introduction of rapid, alternative methods to
identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect
Dis 47: 487–495.
23. Albert H (2004) Economic analysis of the diagnosis of smear-negative pulmonary
tuberculosis in South Africa: incorporation of a new rapid test, FASTPlaqueTB,
into the diagnostic algorithm. Int J Tuberc Lung Dis 8: 240–247.
24. Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, et al. (2012) The cost-
effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to
initiation of antiretroviral therapy: a model-based analysis. AIDS 26: 987–995
910.1097/QAD.1090b1013e3283522d3283547.
TB Diagnostics Modeling: A Systematic Review
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e110558
25. Bonnet M, Tajahmady A, Hepple P, Ramsay A, Githui W, et al. (2010) Added
value of bleach sedimentation microscopy for diagnosis of tuberculosis: a cost-
effectiveness study. Int J Tuberc Lung Dis 14: 571–577.
26. Dowdy DW, Lourenco MC, Cavalcante SC, Saraceni V, King B, et al. (2008)
Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-
infected Brazilian adults. PLoS One 3: e4057.
27. Dowdy DW, Maters A, Parrish N, Beyrer C, Dorman SE (2003) Cost-
effectiveness analysis of the gen-probe amplified mycobacterium tuberculosis
direct test as used routinely on smear-positive respiratory specimens. Journal of
clinical microbiology 41: 948–953.
28. Dowdy DW, Steingart KR, Pai M (2011) Serological testing versus other
strategies for diagnosis of active tuberculosis in India: a cost-effectiveness
analysis. PLoS Med 8: e1001074.
29. Guerra RL, Hooper NM, Baker JF, Alborz R, Armstrong DT, et al. (2008) Cost-
effectiveness of different strategies for amplified Mycobacterium tuberculosis
direct testing for cases of pulmonary tuberculosis. J Clin Microbiol 46: 3811–
3812.
30. Hughes R, Wonderling D, Li B, Higgins B (2012) The cost effectiveness of
Nucleic Acid Amplification Techniques for the diagnosis of tuberculosis.
Respiratory medicine 106: 300–307.
31. Lim TK, Cherian J, Poh KL, Leong TY (2000) The rapid diagnosis of smear-
negative pulmonary tuberculosis: a cost-effectiveness analysis. Respirology 5:
403–409.
32. Meyer-Rath G, Schnippel K, Long L, Macleod W, Sanne I, et al. (2012) The
Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa. PLoS
One 7: e36966.
33. Rajalahti I, Ruokonen EL, Kotomaki T, Sintonen H, Nieminen MM (2004)
Economic evaluation of the use of PCR assay in diagnosing pulmonary TB in a
low-incidence area. Eur Respir J 23: 446–451.
34. Schnippel K, Meyer-Rath G, Long L, Stevens WS, Sanne I, et al. (2013)
Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative
algorithms for South Africa. S Afr Med J 103: 101–106.
35. Sun D, Dorman S, Shah M, Manabe YC, Moodley VM, et al. (2013) Cost utility
of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-
infected African adults. Int J Tuberc Lung Dis 17: 552–558.
36. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, et al. (2011) Rapid
diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden
countries: a cost-effectiveness analysis. PLoS Med 8: e1001120.
37. Dowdy DW, O’Brien MA, Bishai D (2008) Cost-effectiveness of novel diagnostic
tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 12: 1021–1029.
38. Jones TF, Schaffner W (2001) Miniature chest radiograph screening for
tuberculosis in jails: a cost-effectiveness analysis. Am J Respir Crit Care Med
164: 77–81.
39. Maheswaran H, Barton P (2012) Intensive case finding and isoniazid
preventative therapy in HIV infected individuals in Africa: economic model
and value of information analysis. PLoS One 7: e30457.
40. Resch SC, Salomon JA, Murray M, Weinstein MC (2006) Cost-effectiveness of
treating multidrug-resistant tuberculosis. PLoS Med 3: e241.
41. Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, et al. (2011)
Costs and consequences of additional chest x-ray in a tuberculosis prevention
program in Botswana. Am J Respir Crit Care Med 183: 1103–1111.
42. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr, et al.
(2009) Epidemiological benefits of more-effective tuberculosis vaccines, drugs,
and diagnostics. Proc Natl Acad Sci U S A 106: 13980–13985.
43. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE (2008) Impact
of enhanced tuberculosis diagnosis in South Africa: a mathematical model of
expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A 105:
11293–11298.
44. Dowdy DW, Chaisson RE, Moulton LH, Dorman SE (2006) The potential
impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a
mathematical model. AIDS 20: 751–762.
45. Barter DM, Agboola SO, Murray MB, Barnighausen T (2012) Tuberculosis and
poverty: the contribution of patient costs in sub-Saharan Africa–a systematic
review. BMC Public Health 12: 980.
TB Diagnostics Modeling: A Systematic Review
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e110558
